Avalanche Biotechnologies Inc. (NASDAQ:ADVM) shares traded down 4.8% during trading on Tuesday . The stock traded as low as $4.37 and last traded at $4.53, with a volume of 77,411 shares. The stock had previously closed at $4.76.

Several research analysts have commented on the stock. Jefferies Group reissued a “buy” rating and set a $12.00 price target on shares of Avalanche Biotechnologies in a research note on Wednesday, August 10th. Zacks Investment Research raised shares of Avalanche Biotechnologies from a “sell” rating to a “hold” rating in a research note on Tuesday, July 19th. Chardan Capital downgraded shares of Avalanche Biotechnologies from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $7.50 to $5.00 in a research note on Wednesday, June 8th. Finally, Cowen and Company assumed coverage on shares of Avalanche Biotechnologies in a research note on Friday, May 27th. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $9.06.

The stock’s market cap is $186.07 million. The stock has a 50-day moving average of $3.58 and a 200 day moving average of $4.50.

Avalanche Biotechnologies (NASDAQ:ADVM) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $1.38. On average, equities analysts forecast that Avalanche Biotechnologies Inc. will post ($1.81) EPS for the current fiscal year.

Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.